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(p = 0.005) improved significantly with the natural mineral 
water as compared to placebo.
Conclusions The daily consumption of a natural mineral 
water rich in magnesium sulphate and sodium sulphate 
improved bowel movement frequency and stool consist-
ency in subjects with functional constipation. Moreover, 
the subjects’ health-related quality of life improved.
Clinical Trial Registration EudraCT No 2012-005130-11.
Keywords Bowel function · Stool frequency and 
consistency · Natural mineral water · Clinical trial
Introduction
Constipation is one of the leading bowel conditions affect-
ing health-related quality of life but also comprising other 
complaints resulting in substantial healthcare costs [1–3]. 
Functional constipation is a functional gastrointestinal dis-
order characterized by straining during defecation, lumpy 
or hard stool, sensation of incomplete evacuation and infre-
quent bowel movements without evident organic or struc-
tural diseases [4]. An integrative review of eleven studies 
conducted in Asian, South American and European coun-
tries revealed a prevalence of constipation ranging from 2.6 
to 26.9 % in the general adult population [5]. In Europe, a 
mean prevalence rate of 17.1 % was reported [6].
In principle, the spectrum of stool types in the general 
healthy population is wide including hard, fragmented 
lumps to sausage-like or snake-like forms up to mushy 
material, which correlates with transit time and faecal bulk 
[7]. The water content of stool usually ranges from 70 to 
80 %, while constipated subjects have a harder stool with 
water content below 70 % [8]. Stool consistency is fre-
quently related to bowel movement, which also differs 
Abstract 
Purpose The present placebo-controlled, double-blind, 
randomized trial aimed to investigate whether a natural 
mineral water rich in magnesium sulphate and sodium sul-
phate (Donat Mg) may help to improve bowel function.
Methods A total of 106 otherwise healthy subjects with 
functional constipation were randomly assigned to con-
sume 300 or 500 mL of a natural mineral water as com-
pared to placebo water, over a course of 6 weeks. The 300-
mL arms were terminated due to the results of a planned 
interim analysis. Subjects documented the complete spon-
taneous bowel movements, spontaneous and overall bowel 
movements/week, stool consistency, gastrointestinal symp-
toms and general well-being in a diary. Change in the 
number of complete spontaneous bowel movements was 
defined as the primary outcome.
Results For the 75 subjects in the 500-mL arms, the 
change in the number of complete spontaneous bowel 
movements per week tended to be higher in the active 
group when compared to placebo after 6 weeks (T2 = 1.8; 
pvalue = 0.036; one-sided). The mean number of spon-
taneous bowel movements significantly increased over 
the course of the study, with significant differences 
between study arms considering the whole study time (F 
test = 4.743; ptime × group = 0.010, 2-sided). Stool consist-
ency of spontaneous bowel movements (p < 0.001) and the 
subjectively perceived symptoms concerning constipation 
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considerably between individuals, with a mean frequency 
of one stool per day reported for people living in Western 
countries [9].
Generally, the aetiology of constipation is very complex 
and mainly influenced by dietary factors including drinking 
habits and a sedentary lifestyle; hence, changes in lifestyle 
and diet are usually the first recommendation for consti-
pated subjects [10]. The use of laxatives, bulking agents, 
stool softeners or other remedies is recommended if life-
style modifications fail. These might, however, be associ-
ated with side effects; furthermore, according to a recent 
survey in ten European countries, 28 % of subjects were 
dissatisfied with their current constipation treatment [10].
In a cross-sectional study on Japanese women, a low 
intake of magnesium and water from food was inversely 
associated with the prevalence of functional constipation. 
Indeed, magnesium salts such as magnesium sulphate are 
known for their osmotic effects accelerating intestinal tran-
sit time and leading to better stool consistency [11, 12]. 
Natural mineral waters rich in magnesium salts are there-
fore thought to improve bowel function. So far, controlled 
clinical trials assessing the effect of mineral-rich water on 
bowel function have not been frequently reported [13–15]. 
The aim of the present randomized, controlled interven-
tional study was to examine the effect of a natural mineral 
water rich in magnesium sulphate and sodium sulphate 
as compared to placebo on bowel function in otherwise 
healthy adults with functional constipation.
Methods
Trial design
The study was designed as a mono-centre, parallel-treat-
ment, multi-dose, double-blind study in subjects with 
functional constipation. The trial incorporated a planned, 
adaptive interim analysis to adjust for sample size and to 
evaluate the different doses with regard to the main study 
objective. The first part of the study was performed with 
four study arms: two arms with a daily dose of 300 mL 
(active and placebo) and two arms with a daily dose 
of 500 mL (active and placebo). Following the interim 
analysis, the lower-volume/lower-dose arms were termi-
nated, and the final sample size (for the 500 mL dose) was 
adjusted. Results for the lower dose are not presented.
The study was approved by the Ethics Committee 
(Office for Health and Social Affairs, Berlin, Germany) and 
by the Competent Authority (Federal Institute for Drugs 
and Medical Devices, Bonn, Germany). It was conducted in 
compliance with the Declaration of Helsinki as well as the 
German Pharmaceuticals Act, the principles of ICH-GCP, 
and the German GCP-V. The study was registered in the 
European Clinical Trials Database (EudraCT) as EudraCT 
No 2012-005130-11. Participants gave written informed 
consent prior to the study.
Subjects
A total of 106 otherwise healthy subjects with functional 
constipation were enrolled to the study site in Berlin, Ger-
many. Subjects aged 18–70 with functional constipation 
according to ROME III criteria having two-to-four bowel 
movements per week during the preceding months were 
included [4, 16]. They were asked to adhere to their for-
mer diet and physical activity and had to be used to con-
suming at least 300 mL of water (incl. tea). Women of 
childbearing potential had to agree to use contraception 
methods. The exclusion criteria were as follows: acute 
gastritis and enteritis, bleeding tendency and risk of rup-
ture in the intestinal tract, disorders in motility and secre-
tion in the digestive tract, acute or chronic disease of the 
gastrointestinal tract, irritable bowel syndrome, abdominal 
pain, abdominal surgery within the last 6 months prior to 
study start, known pelvic floor dysfunction, susceptibility 
to development of kidney stones, hyperresorptive hypercal-
ciuria with urinary stones, urinary infections with E. coli, 
renal insufficiency, acute or chronic kidney or urinary tract 
disease, alkalosis, severe respiratory disease, cardiovas-
cular system insufficiency, acute inflammatory diseases, 
dehydrated conditions, restricted fluid tolerance, acute or 
chronic neurological or psychiatric illness, weight loss of 
≥3 kg within the last 3 months prior to the study, clinically 
relevant excursions of laboratory parameters, BMI > 35 kg/
m2, thyroid dysfunction, known sensitivity to the ingre-
dients of the product, use of any preparations that could 
affect the gastrointestinal tract during the last 2 weeks and 
during the study (except rescue medication, a bisacodyl 
suppository that could be used in case of no bowel move-
ments for 4 days; max. four suppositories were permitted 
during the entire study), use of sympathomimetics and car-
diac glycosides, supplementation of magnesium, vitamins 
or other minerals during the study, intake of mineral water 
other than the study product during the study, pregnancy or 
nursing, drug, alcohol or medication abuse, participation in 
another clinical trial during the last 30 days prior to study 
start, relationship with or dependence on the sponsor or the 
investigator, problems with complying with or following 
the protocol due to language difficulties, or commitment to 
an institution by virtue of an order issued either by the judi-
cial or the administrative authorities.
Furthermore, subjects had to fulfil the following ran-
domisation criteria during the run-in period before obtain-
ing the investigational product (assessed per subject diary): 
two-to-four bowel movements per week and intake of at 
least 300 mL water (incl. tea) daily.
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Intervention
During the study period of 6 weeks, the subjects consumed 
their daily dose of Donat Mg natural mineral water or pla-
cebo in two portions: prior to breakfast and in the evening 
before dinner. Donat Mg natural mineral water is derived 
from a spring in Rogaska Slatina, Slovenia. It is enriched 
by minerals from dissolving rocks 280-600 m under ground 
providing Donat Mg with 13 g/L of dissolved mineral 
substances. Both the mineral water and the placebo were 
produced and bottled by Droga Kolinska, d.d (Slovenia). 
Main ingredients of Donat Mg natural mineral water are 
sodium (1600 mg/L), magnesium (1000 mg/L), calcium 
(370 mg/L), sulphate (2000 mg/L), and hydrogen carbon-
ate (7600 mg/L). The placebo was sparkling water derived 
from another spring in Rogaska Slatina with a low con-
tent of minerals (<1 mg/L sodium, 30 mg/L magnesium, 
73 mg/L calcium, 17 mg/L sulphate, 390 mg/L hydrogen 
carbonate) and a quantity of CO2 (3.5 g/L) comparable to 
the active product.
The clinical phase of the study included a run-in 
period of 10 ± 2 days and an intervention period of 
6 weeks ± 3 days. A total of five visits were performed: 
a screening visit, a baseline visit (after the run-in period), 
a telephone visit 7 ± 3 days after baseline, a control visit 
21 ± 3 days after baseline and the final visit 42 ± 3 days 
after baseline.
Compliance was checked by counting returned unused 
investigational product and assessing the trial duration. The 
accepted compliance rate was defined as 75–125 % of the 
correct quantity of investigational product and max. 3 days 
deviation from the 6-week study period.
Outcome measures
The primary outcome was the subject-rated change in 
the number of complete spontaneous bowel movements 
(CSBMs) per week between placebo and active over the 
course of the study. A CSBM was defined as a bowel move-
ment with sensation of complete evacuation and with no 
laxative/enema in the 24 h preceding the bowel movement. 
In addition, the number of overall bowel movements (BM), 
the number of spontaneous bowel movements (SBM, bowel 
movements with no laxative/enema in the 24 h preceding 
the bowel movement) and the number of complete bowel 
movements (CBM, defined as bowel movements with a 
sensation of complete evacuation) were assessed. Subjects 
were asked to record their stool consistency using Bristol 
Stool Form Scale (BSFS) questionnaire [17].
Subjects had to document their daily bowel movements, 
the respective stool form, the sensation of complete evacu-
ation following defecation (yes/no) and whether they had 
used any rescue medication in a daily diary. In addition, 
subjects had to fill in the questionnaires Gastrointestinal 
Symptoms Rating Scale (GSRS) [18], the Short Form 12 
Health Survey Questionnaire (SF-12) [19] and the short 
form of the international physical activity questionnaire 
(IPAQ-SF) at each visit post screening [20]. Eating and 
drinking habits were recorded in a diary on 3 days of each 
week (to calculate the mean answer to the items regarding 
intake of certain foods/day, the following score was used: 
none = 1, once = 2, twice or three times = 3, more than 
three times = 4; the intake of liquids was recorded in mL). 
The efficacy of the investigational products was evaluated 
by the participants and the investigator independently at 
the end of the study by means of a global-scaled evaluation 
with “very good”, “good”, “moderate” or “poor”.
Biochemical parameters such as liver function and lipid 
parameters as well as blood pressure and heart rate were 
assessed at screening and at the end of the intervention.
Adaptive design and statistics
The adaptive interim analysis was scheduled to take place 
when data from 50 % of originally planned number of sub-
jects were available [21]. The analysis was done by an inde-
pendent statistician using the full analysis set (FAS). An 
Independent Data Monitoring Committee (IDMC) was in 
place to provide appropriate recommendations to the trial 
sponsor while all staff involved in the conduct of the trial 
remained blind to the results of the interim analysis. Two 
sets of one-sided confirmatory hypotheses were planned to 
be tested at the interim and final analysis for the primary 
efficacy variable dCSBM in each of the dose groups (i.e. 
300 mL each verum or placebo; 500 mL each verum or pla-
cebo) (Table 1).
The trial results were analysed according to a two-stage 
adaptive group sequential design with one interim analysis 
using O’Brien and Fleming stopping boundaries [21]. Each 
hypothesis was tested (at the interim and final analysis) 
Table 1  Splitting of the overall 
type I error
Alpha (one-sided) Stage Analysis Critical value to reject H0
H(01) H(02)
Test statistic Alpha (one-sided) Test statistic Alpha (one-sided)
0.025 1 Interim 3.011 0.0013 2.797 0.0026
2 Final 2.257 0.0120 1.977 0.0240
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with the nonparametric one-sided Mann–Whitney U test. 
The inverse-normal method was used to combine the p 
values for each of the two sets of one-sided confirmatory 
hypotheses [22].
The overall experiment-wise significance level [i.e. the 
family-wise error rate (FWER)] was set to = 0.025 (one-
sided). Adjustment of the significance level was performed 
to control the overall type I error = 0.025 (one-sided). 
In the interim analysis, the null hypotheses could not 
be rejected for any of the dose levels. The IDMC recom-
mended stopping the low-volume-dose groups and to adjust 
the sample size for the higher dose. The final analysis of 
the primary endpoint was only performed for the 500-mL 
dose with the test statistic T2 critical value to reject the null 
hypothesis of 1.977. The secondary outcome parameters 
were tested in the exploratory sense using the nonparamet-
ric procedures Mann–Whitney U test, Wilcoxon test and 
Chi-square test. Changes in clinical parameters over time 
were analysed by using exploratory ANOVA. The analy-
sis was performed using the FAS and at least for the pri-
mary outcome in addition using the valid case analysis set 
(VCAS).
Sample size estimation
For the sample size estimation before the interim analysis, 
the calculation was based on the assumption of an effect 
size of 0.7 for the lower dose and 1.0 for the higher dose. 
The sample size re-estimation for the study continuation 
with the higher dose was calculated based on the target 
conditional power using the procedure suggested by Chang 
[23]. The initial estimates and the observed treatment dif-
ference and standard deviation at the interim analysis were 
considered. The conditional power was set to 80 %. Critical 
value α2 for the final analysis was set to 0.0240.
Results
Subject recruitment
Out of the 132 subjects assessed for eligibility, 106 were 
randomized (Fig. 1); 30 subjects thereof were allocated to 
the 300-mL arms, which were terminated after the interim 
analysis (data not shown). Of the 76 subjects allocated to 
the 500-mL arms, 75 were included in the FAS population 
(one subject had no data except baseline).
Characteristics of study subjects at baseline
Of the 75 subjects in the 500-mL arms, 63 were female and 
12 were male with functional constipation according to 
ROME III (Table 2). The baseline characteristics, including 
the eating and drinking habits and physical activity did not 
differ between interventional groups.
Bowel movements
All bowel movements analysed were spontaneous; hence, 
the results given for CSBMs are also valid for CBM assess-
ment and those for SBMs accordingly for BM assessment. 
The change in the number of complete spontaneous bowel 
movements per week tended to be higher in the active 
group as compared to placebo after 6 weeks (test statis-
tic T2 = 1.8; combined pvalue = 0.036 with a confirma-
tory significance level of 0.024; one-sided). There was 
a trend between the active group and the placebo group 
regarding the changes in CSBMs over time (F test: 2.992; 
ptime × group = 0.054; Table 3).
The mean number of SBMs/BMs almost doubled after 
6 weeks of drinking the mineral-rich water, with signifi-
cant differences between study arms considering the whole 
study time (F test = 4.743; ptime × group = 0.010, Table 3). 
After three and 6 weeks, respectively, the number in SBMs/
BMs was significantly higher in subjects drinking the 
mineral-rich water as compared to those drinking placebo 
water (p = 0.006 and p = 0.001, respectively).
Similar results were shown for VCAS; there were no sta-
tistically significant differences between the active and pla-
cebo groups in changes in CSBMs per week (p = 0.154), 
while for the SBMs/BMs the groups differed significantly 
(p = 0.024).
Stool consistency
With regards to the consistency of SBMs/BMs, 78.4 % in 
the active group and 60.5 % in the placebo group reported 
that the stool became softer after 6 weeks of intake, while 
8.1 % and 23.7 % in the corresponding groups showed 
a harder stool as compared to baseline (pactive < 0.001; 
pplacebo = 0.012). At week 3 and 6, subjects in the active 
group had a significant softer stool than the placebo group 
(p = 0.001 and p < 0.001, respectively; Fig. 2). The stool 
consistency of SBMs/BMs throughout the study differed 
significantly between study groups (F test = 12.376; 
ptime × group < 0.001).
Gastrointestinal symptoms and general well‑being
The gastrointestinal symptoms were assessed by means 
of the GSRS. In line with the increased number of bowel 
movements and stool consistency score, subjects drink-
ing the mineral-rich water experienced an improvement in 
the symptoms related to constipation throughout the study 
(p = 0.005), while other symptom clusters and the total 
sum score did not differ between study arms (Table 4).
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In addition, there were significant differences between 
the mineral-rich water group and the placebo group with 
regards to changes in the SF-12 sum score from baseline to 
week 6 (p = 0.017).
Physical performance and dietary habits
Physical activity was not changed in any of the study 
groups over the course of the study (p = 0.628). There was 
no significant difference between study groups in the con-
sumption of beverages throughout the entire study. At the 
end of the intervention, the active group ate slightly more 
dried fruits (from 1.04 at baseline to 1.15 at 6 weeks) and 
carrots/potatoes (from 1.53 at baseline to 1.68 at 6 weeks) 
as compared to placebo (1.04 at baseline to 1.03 at 6 weeks 
for dried fruits, p = 0.04; 1.68 at baseline to 1.60 at 
6 weeks for carrots/potatoes; p = 0.03).
Global evaluation of the efficacy
At the end of the study, 94.5 % of subjects in the min-
eral-rich water group—compared to 57.9 % in the pla-
cebo group—rated the global evaluation of efficacy as 
“very good” or “good”. Similarly, the physicians rated the 
Analysed  (n=37) Analysed (n=38) 
Analysis 500ml
(n=75)
Allocated to intervention mineral water (n=58) 
Received allocated intervention (n=58) 
Received allocated intervention 500 ml (n=38) 
Allocated to intervention placebo (n=48) 
Received allocated intervention (n=48) 
Received allocated intervention 500 ml 
(n=38) 
Lost to follow-up (n= 1) Lost to follow-up (n=0) 
Follow-Up
Assessed for eligibility (n=132)
Excluded (n=26) 
Screen failure (n=10) 
Not meeting randomization criteria (n=10) 






Fig. 1  Subject flow chart
Table 2  Baseline 
characteristics of study subjects
p values (Mann–Whitney U test) for differences between study arms
Total Active Placebo p
Gender (f/m) 63/12 31/6 32/6 0.960
Age 46.4 ± 12.6 46.8 ± 12.9 46.0 ± 12.5 0.707
Weight (cm) 70.6 ± 11.9 71.1 ± 13.6 70.2 ± 10.2 0.899
Systolic blood pressure (mmHg) 115.2 ± 12.1 113.9 ± 11.3 116.5 ± 12.9 0.332
Diastolic blood pressure (mmHg) 75.4 ± 6.6 74.9 ± 6.2 75.9 ± 7.0 0.419
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mineral-rich water as “very good” or “good” for 97.2 % of 
the participants, while they gave the same rating for 57.9 % 
of the participants consuming the placebo water. Both par-
ticipants and physicians rated the efficacy of the mineral-
rich water better than the placebo water (pchi = 0.001 and 
pchi < 0.001, respectively).
Safety evaluation, laboratory parameters and use 
of rescue medication
A total of 16 adverse events occurred during the study 
period in the 500-mL arm with no statistical differ-
ence between the mineral water group and placebo 
group (p = 0.571). Twelve occurred in the active group, 
and another four events were recorded in the placebo 
group. One case in the active group might be related to 
the intervention. In two cases of the active group, the 
causality of the adverse event was probably related to 
the intervention. One adverse event in the active group 
was classified as serious but was not related to the 
intervention.
None of the measured clinical parameters including 
liver enzymes, triglycerides, cholesterol, HDL-C, LDL-C, 
blood pressure and heart rate values differed between study 
groups.
With regards to rescue medication, no difference was 
observed between groups regarding the intake of rescue 
medication (p = 0.240).
There were no statistically significant differences 
between groups in deviation of the actual intake of inves-
tigational products from expected intake (p > 0.1). The 
compliance rate considering the intake of the investiga-
tional product was 102 % ± 8.6 in the active group and 
105 % ± 9.4 in the placebo group.
Table 3  Mean (SD) number of CSBMs per week and SBMs/BMs 
per week during a 6-week intervention with mineral-rich water or 
placebo water
pU values (Mann–Whitney U test) for differences between study arms
pANOVA for RM-ANOVA (time × group interaction)
Active Placebo pU
Mean SD Mean SD
CSBMs per week
 Baseline 0.68 (1.11) 0.79 (1.10) 0.629
 Week 3 2.19 (3.19) 1.26 (1.64) 0.353
 Week 6 2.14 (2.67) 1.16 (1.50) 0.173
 pANOVA 0.054
SBMs/BMs per week
 Baseline 3.38 (1.26) 3.03 (0.92) 0.329
 Week 3 6.14 (3.32) 4.45 (2.09) 0.006














Fig. 2  Stool consistency SBM/BM using bristol stool form scale 
(BSFS type, median, interquartile range, range) over the course of the 
intervention (grey active group, white placebo group). Bristol stool 
score—1 for hard lumps to seven watery stools. *p values (Mann–
Whitney U test) for differences between study arms
Table 4  Mean (SD) of gastrointestinal symptom rating scale (GSRS)
pUΔ values (Mann–Whitney U test) for differences between study 
arms in changes in GSRS dimension between baseline and final visit
p values (Mann–Whitney U test) for differences between study arms
Active Placebo p
Mean SD Mean SD
GSRS (reflux)
 Baseline 1.54 0.96 1.37 0.72 0.413
 Week 6 1.39 0.63 1.45 0.79 0.990
 pUΔ 0.348
GSRS (abdominal pain)
 Baseline 1.90 0.74 1.96 0.80 0.797
 Week 6 1.66 0.74 1.68 0.72 0.773
pUΔ 0.944
GSRS (indigestion)
 Baseline 2.75 1.19 2.72 1.02 0.924
 Week 6 2.26 1.13 2.30 0.99 0.617
 pUΔ 0.915
GSRS (diarrhoea)
 Baseline 1.23 0.49 1.23 0.56 0.492
 Week 6 1.64 1.04 1.35 0.55 0.392
 pUΔ 0.335
GSRS (constipation)
 Baseline 3.82 1.48 3.59 1.38 0.419
 Week 6 1.81 0.79 2.56 1.14 0.001
 pUΔ 0.005
GSRS (total)
 Baseline 2.33 0.76 2.26 0.70 0.722
 Week 6 1.81 0.58 1.92 0.66 0.442
 pUΔ 0.327
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Discussion
The present placebo-controlled, randomized, double-blind 
intervention study in subjects with functional constipation 
provides clinical evidence that drinking a mineral water 
rich in magnesium sulphate and sodium sulphate over a 
course of 6 weeks can confer significant benefits for diges-
tive health. The improvement in the constipation symptoms 
as reflected by an increased number of CSBMs and over-
all bowel movements per week and a softer stool in com-
parison with a water low in minerals confirmed previous 
assumptions of the digestion stimulating effects of waters 
naturally rich in minerals. Indeed, the number of CSBMs/
week more than tripled within the course of the study in 
subjects drinking the mineral-rich water, which is compara-
ble to the effect of psyllium and dried plums demonstrating 
an increase in the mean number of CSBMs/week by more 
than a double [24].
In line with the improved objective parameters of bowel 
function, study participants experienced an improvement in 
the GSRS dimension constipation exceeding the minimal 
clinically relevant score change of 0.5 [25] together with an 
overall increase in the health-related quality of life.
The change in the number of CSBMs per week was cho-
sen as the primary endpoint as it is considered the more 
sensitive assessment with regards to the overall bowel func-
tion as information on the completeness of bowel move-
ment is also provided [26]. Since there was no adequate 
and well-controlled trial with the investigational product 
available at the time the current study was planned, an 
adaptive study design was applied to adjust the sample size, 
if necessary or to terminate the entire trial, the low- (300-
mL) or the high- (500-mL) volume dose arms earlier if effi-
cacy in the primary endpoint is lacking or already achieved 
at the interim analysis. In terms of CSBMs, participants did 
not seem to benefit from drinking 300 mL of the mineral 
water per day, and therefore these arms of the study were 
closed, while the sample size of the 500-mL dose group 
was increased based on the results of the interim analy-
sis. Given the outcomes of this clinical trial, the intake of 
500 mL of Donat Mg per day seems to improve CSBMs 
but also overall bowel movements and consistency more 
efficiently than the 300-mL dose.
As dietary habits and lifestyle factors are thought to 
impact bowel function, the subjects’ eating and drinking 
habits and physical activity levels were assessed. Only a 
marginal increase in the consumption of dried fruits was 
observed in the active group as compared to placebo over 
the course of the study. Given the semi-quantitative nature 
of the dietary assessment and the observed small differ-
ences between study groups, it is highly unlikely that this 
change might have had an impact on the study results.
The outcome of the present clinical trial is in agreement 
with another recently published study comparing different 
dosages of a mineral water with placebo. In that trial, the 
daily consumption of 1 L magnesium sulphate-rich mineral 
water (119 mg/L magnesium, 1530 mg/L sulphate) reduced 
constipation and improved stool consistency in function-
ally constipated women [13]. Although the study group was 
limited to women and the primary endpoint was response 
to the treatment as assessed by components of the Rome 
III criteria, while the number of bowel movements was not 
reported, this study confirms the beneficial effect of a natu-
ral mineral water rich in magnesium and sulphate on bowel 
function.
In the present study, a mineral water containing 13 g/L 
of dissolved mineral substances, among them magnesium 
sulphate and sodium sulphate was investigated. Magnesium 
sulphate exerts its osmotic effect by trapping water in the 
intestinal lumen, resulting in increased and softer faecal 
bulk, which presses on the intestinal wall provoking peri-
stalsis [27, 28]. A study in healthy human subjects demon-
strated that high doses of orally administered magnesium 
sulphate accelerate small intestinal transit time and modu-
late antroduodenal motility in the fasting but not in the 
postprandial state [11]. More recently, in vivo and in vitro 
studies showed that, along with the magnesium sulphate-
induced change in the osmotic pressure, the expression of 
osmoregulatory genes is induced [29, 30]. In addition, the 
expression of Aquaporin 3, a gene involved in the regula-
tion of faecal water content in the colon, was increased in 
the rat colon after administration of magnesium sulphate 
[30]. Another study in rats reported that the laxative effect 
of magnesium sulphate may involve the release of nitric 
oxide (NO) through the stimulation of NO synthase [31]. 
Sulphate is further known to increase faecal bulk and stool 
consistency, and water containing more than 1000 mg/L 
sulphate was linked to a self-reported laxative effect [32, 
33]. Overall, the effect on stool frequency and consistency 
of the investigated mineral water is most likely related to its 
naturally high content of magnesium and sulphate.
Some limitations of the study should be noted. In addi-
tion to the effect of the mineral water on constipation, its 
influence on the entire gastrointestinal tract and the over-
all quality of life was evaluated. However, it might have 
been more appropriate to use constipation-specific ques-
tionnaires to assess the respective symptoms and quality 
of life rather than the more general tools applied in the 
study. Further, after 50 % of the originally planned number 
of subjects have been recruited, the lower-dose group was 
stopped based on the recommendation made by the IDMC. 
Yet, the sample size might have been too small to draw a 
firm conclusion for the 300-mL group. Further clinical tri-
als with larger sample size might investigate an effect of 
the mineral-rich water. In addition, measuring other gut 
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health-related parameters such as faecal bulk, transit time 
or a potential impact on microbiota would further elucidate 
the underlying mode of action.
In summary, the presented study in otherwise healthy 
subjects confirms the beneficial effect of drinking 
500 mL natural mineral water daily on bowel function 
in subjects with functional constipation. In addition, the 
consumption of this specific mineral water was proven 
to be safe and tolerable. The observed results support the 
postulation that a mineral water naturally rich in magne-
sium sulphate and sodium sulphate may be considered as 
a first line of recommendation for subjects with less fre-
quent bowel movements or harder stool in order to main-
tain a normal defecation. This in turn may help to reduce 
gastrointestinal discomfort and the development of dis-
eases frequently associated with constipation. Finally, 
this might improve the health-related quality of life and 
subsequently reduce the economic burden on healthcare 
resources.
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